Thomas F. Unger, PhD, MBA Bigfinite

Thomas Unger is an advisor assisting companies ranging from Fortune 500 to startups, helping establish and shape their futures in healthcare. He works broadly across the sector, with clients in high-technology, academic centers, biopharmaceutical and healthcare. In the area of digital health, he is actively working with companies developing next generation computational architecture, machine learning/AI, data models and analytics, spanning early R&D to point-of-care.

Thomas was previously at Pfizer Inc. where he held a number of senior roles in the R&D organization. Before joining Pfizer, his career included positions at the investment banking firm Aperion Partners, LLC and MTM Advisors, LLC, and management consulting firms including PA Consulting Group. Thomas has been a co-founder of a number of early stage biotechnology companies including Naia Pharma, BioLogic Technologies and Miragen Incorporated.

While at Pfizer, Thomas was responsible for initiating a number collaborative innovation initiatives, including that as a co-founder of MIT/NEWDIGS (NEW Drug development paraDIGmS). NEWDIGS laid the foundation for EMA’s recently launched MAPPS initiative. He currently serves on the Advisory Boards of a number of emerging biotech companies, foundations and academic Centers including the Center for Assessment Technology and Continuous Health (CATCH) at Massachusetts General Hospital and UCSF’s Center for Digital Health Innovation. Thomas is a Science Advisor to bigfinite.